G. Ucar Et Al. , "Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?," CUREUS , vol.12, no.9, 2020
Ucar, G. Et Al. 2020. Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?. CUREUS , vol.12, no.9 .
Ucar, G., Acikgoz, Y., Ergun, Y., Bal, O., Yilmaz, M., Karakaya, S., ... Akdeniz, N.(2020). Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?. CUREUS , vol.12, no.9.
Ucar, Gokhan Et Al. "Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?," CUREUS , vol.12, no.9, 2020
Ucar, Gokhan Et Al. "Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?." CUREUS , vol.12, no.9, 2020
Ucar, G. Et Al. (2020) . "Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?." CUREUS , vol.12, no.9.
@article{article, author={Gokhan Ucar Et Al. }, title={Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?}, journal={CUREUS}, year=2020}